CN Patent

CN110343135A — 替诺福韦艾拉酚胺(tenofovir alafenamide)半反丁烯二酸盐

Assigned to Gilead Sciences Inc · Expires 2019-10-18 · 7y expired

What this patent protects

本发明描述9‑[(R>2‑[[(S)‑[[(S>1‑(异丙氧羰基)乙基]氨基]苯氧基氧膦基]m(替诺福韦艾拉酚胺(tenofovir alafenamide))的半反丁烯二酸盐形式和使用替诺福韦艾拉酚胺半反丁烯二酸盐的抗病毒疗法(例如抗HTV和抗HBV疗法)。

USPTO Abstract

本发明描述9‑[(R>2‑[[(S)‑[[(S>1‑(异丙氧羰基)乙基]氨基]苯氧基氧膦基]m(替诺福韦艾拉酚胺(tenofovir alafenamide))的半反丁烯二酸盐形式和使用替诺福韦艾拉酚胺半反丁烯二酸盐的抗病毒疗法(例如抗HTV和抗HBV疗法)。

Drugs covered by this patent

Patent Metadata

Patent number
CN110343135A
Jurisdiction
CN
Classification
—
Expires
2019-10-18
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.